Last updated: 2026-09-16 09:46:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
YD Bio Limited (YDES) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $3.94, with a market capitalisation of $271.33M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.70 to $22.00. This page covers its latest market performance, valuation, price trends and company information.
$271.33M | |
$3.79 | |
$25.00 | |
$1.70 | |
$3.83 | |
687.02K | |
245.71K | |
-- | |
$22.00 | |
$1.70 | |
-- | |
-- |
YD Bio Limited (YDES) is trading at $3.78 in pre-market trading as of 2026-09-15 19:57:40, down 1.31% ($0.05) from the previous close of $3.83
Pre-market trading shows how investors are pricing YDES before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, YD Bio Limited (YDES) moved from $3.54 to $3.94, representing a gain of 11.19% ($0.40).
The stock traded between $3.29 and $4.50 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 655.10 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 11.0%
YDES is currently trading at $3.94, placing it 11.0% of the way from its 52-week low of $1.70 to its 52-week high of $22.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of YD Bio Limited (YDES) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.